Cardiome Pharma Corp. (NASDAQ: CRME) 20.2% LOWER; Announced that its co-development partner, Astellas Pharma US, Inc., has received a "refusal ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE